Salicylic acid 6% Gel

Manufacturer
SOLUTECH PHARMACEUTICALS LLC
Effective date
2018-03-20
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
1
Source
full-release
Hydrated at
2026-05-31 20:25:34

Label at a glance#

ProductSALICYLIC ACID
Active ingredientSALICYLIC ACID
Label structure12 sections

Indications and uses

Salicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles). Salicylic Acid 6% is a topical aid in the removal of excessive keratin on dorsal and plantar hy...

Dosage and administration

Apply Salicylic Acid 6% Gel to the affected area at night or as directed by your doctor. Preferably, skin should be hydrated for at least five minutes prior to application. The medication is washed off in the morning and if excessive drying and/or irritation is observed a blend cream or lotion may be applied. Unless hands are being treated, hands should be rinsed thoroughly after application. Once desired result i...

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Rx only

For external use only.

Not for ophthalmic use.

Each gram of Salicylic Acid 6% Gel contains:

ACTIVE: 6% Salicylic Acid in a gel base of:

INACTIVES: SD-40 Alcohol, Propylene Glycol, Water and Hydroxyethyl Cellulose

DESCRIPTION

DESCRIPTION SECTION

Salicylic acid is the 2-hydroxy derivative of benzoic acid having the following structure:

Chemical StructureChemical Structure

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Salicylic acid has been shown to produce desquamation of the horny layer of skin while not effecting qualitative or quantitative changes in the structure of the viable epidermis. The mechanism of action has been attributed to a dissolution of intercellular cement substance. In a study of the percutaneous absorption of salicylic acid in a 6% salicylic acid gel in four patients with extensive active psoriasis, Taylor and Halprin showed that the peak serum salicylate levels never exceeded 5 mg/100 ml even though more than 60% of the applied salicylic acid was absorbed. Systemic toxic reactions are usually associated with much higher serum levels (30 to 40 mg/100 ml). Peak serum levels occurred within five hours of the topical application under occlusion. The sites were occluded for 10 hours over the entire body surface below the neck. Since salicylates are distributed in the extracellular space, patients with a contracted extracellular space due to dehydration or diuretics have higher salicylate levels than those with a normal extracellular space. (See PRECAUTIONS.) The major metabolites identified in the urine after topical administration are salicyluric acid (52%), salicylate glucuronides (42%) and free salicylic acid (6%). The urinary metabolites after percutaneous absorption differ from those after oral salicylate administration; those derived from percutaneous absorption contain more salicylate glucuronides and less salicyluric and salicylic acid. Almost 95% of a single dose of salicylate is excreted within 24 hours of its entrance into the extracellular space. Fifty to eighty percent of salicylate is protein bound to albumin. Salicylates compete with the binding of several drugs and can modify the action of these drugs. By similar competitive mechanisms other drugs can influence the serum levels of salicylate. (See Drug Interactions.)

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

For Dermatologic Use

SPL UNCLASSIFIED SECTION

Salicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles).

For Podiatric Use

SPL UNCLASSIFIED SECTION

Salicylic Acid 6% is a topical aid in the removal of excessive keratin on dorsal and plantar hyperkeratotic lesions. Topical preparations of salicylic acid have been reported to be useful adjunctive therapy for verrucae plantares.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Salicylic Acid 6% should not be used in any patient known to be sensitive to salicylic acid or any other listed ingredients. Salicylic Acid 6% should not be used in children under 2 years of age.

WARNINGS

WARNINGS SECTION

Prolonged use over large areas, especially in children and those patients with significant renal or hepatic impairment could result in salicylism. Concomitant use of other drugs which may contribute to elevated serum salicylate levels should be avoided where the potential for toxicity is present. In children under 12 years of age and those patients with renal or hepatic impairment, the area to be treated should be limited and the patient monitored closely for signs of salicylate toxicity: nausea, vomiting, dizziness, loss of hearing, tinnitus, lethargy, hyperpnea, diarrhea, and psychic disturbances. In the event of salicylic acid toxicity, the use of Salicylic Acid 6% should be discontinued. Fluids should be administered to promote urinary excretion. Treatment with sodium bicarbonate (oral or intravenous) should be instituted as appropriate. Patients should be cautioned against the use of oral aspirin and other salicylate containing medications, such as sports injury creams, to avoid additional excessive exposure to salicylic acid. Where needed, aspirin should be replaced by an alternative non-steroidal anti-inflammatory agent that is not salicylate based. Patients should be advised not to apply occlusive dressings, clothing or other occlusive topical products such as petrolatum-based ointments to prevent excessive systemic exposure to salicylic acid. Excessive application of the product other than what is needed to cover the affected area will not result in a more rapid therapeutic benefit. Due to potential risk of developing Reye's syndrome, salicylate products should not be used in children and teenagers with varicella or influenza, unless directed by physician.

PRECAUTIONS

PRECAUTIONS SECTION

For external use only. Avoid contact with eyes, lips, broken or inflamed skin and all mucous membranes. Mild burning or stinging may occur. Peeling of the skin may increase as the salicylic acid works to loosen excess keratin. If excessive burning, stinging or peeling occurs, discontinue use and consult your physician. If swallowed, get medical help or contact Poison Control Center right away. KEEP THIS AND ALL MEDICATION OUT OF THE REACH OF CHILDREN.

DRUG INTERACTIONS

DRUG INTERACTIONS SECTION

The following interactions are from a published review and include reports concerning both oral and topical salicylate administration. The relationship of these interactions to the use of Salicylic Acid 6% is not known.

I.Due to the competition of salicylate with other drugs for binding to serum albumin the following drug interactions may occur:
DRUGDESCRIPTION OF INTERACTION
SulfonylureasHypoglycemia potentiated.
MethotrexateDecreases tubular reabsorption; clinical toxicity from methotrexate can result.
Oral AnticoagulantsIncreased bleeding.
II.Drugs changing salicylate levels by altering renal tubular reabsorption:
DRUGDESCRIPTION OF INTERACTION
CorticosteroidsDecreases plasma salicylate level; tapering doses of steroids may promote salicylism.
Acidifying AgentsIncreases plasma salicylate levels.
Alkanizing AgentsDecreased plasma salicylate levels.
III.Drugs with complicated interactions with salicylates:
DRUGDESCRIPTION OF INTERACTION
HeparinSalicylate decreases platelet adhesiveness and interferes with hemostasis in heparin-treated patients.
PyrazinamideInhibits pyrazinamide-induced hyperuricemia.
Uricosuric AgentsEffect of probenemide, sulfinpyrazone and phenylbutazone inhibited.
The following alterations of laboratory tests have been reported during salicylate therapy:
LABORATORY TESTSEFFECT OF SALICYLATES
Thyroid FunctionDecreased PBI; increased t3 uptake.
Urinary SugarFalse negative with glucose oxidase; false positive with Clinitest with high-dose salicylate therapy (2-5g q.d.).
5-Hydroxyindole acetic acidFalse negative with fluorometric test.
Acetone ketone bodiesFalse positive FeCl3 in Gerhardt reaction; red color persists with boiling.
17-OH corticosteroidsFalse reduced values with >4.8g q.d. salicylate.
Vanilmandelic acidFalse reduced values.
Uric AcidMay increase or decrease depending on dose.
ProthrombinDecreased levels; slightly increased prothrombin time.

PREGNANCY

PREGNANCY SECTION

Category C

TERATOGENIC EFFECTS SECTION

Salicylic acid has been shown to be teratogenic in rats and monkeys. It is difficult to extrapolate from oral doses of acetylsalicylic acid used in these studies to topical administration as the oral dose to monkeys may represent six times the maximal daily human dose of salicylic acid when applied topically over a large body surface. There are no adequate and well controlled studies in pregnant women. Salicylic Acid 6% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Category D in 3rd trimester

SPL UNCLASSIFIED SECTION

It is especially important not to use salicylic acid during the last 3 months of pregnancy unless definitely directed to do so by a doctor because it may cause problems in the unborn child or complications during delivery.

NURSING MOTHERS

NURSING MOTHERS SECTION

Because of the potential for serious adverse reactions in nursing infants from the mother's use of Salicylic Acid 6%, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. If used by nursing mothers, it should not be used on the chest area to avoid accidental contamination of the child.

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

No data are available concerning potential carcinogenic or reproductive effects of Salicylic Acid 6%. It has been shown to lack mutagenic potential in the Ames test.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Some adverse effects are: singing, burning and desquamation.

Peeling of the skin may increase as the salicylic acid works to loosen excess keratin. If excessive burning, stinging or peeling occurs, discontinue use and consult your physician.

Excessive erythema and scaling conceivably could result from use on open skin lesions. Call your physician for medical advice about side effects.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Apply Salicylic Acid 6% Gel to the affected area at night or as directed by your doctor. Preferably, skin should be hydrated for at least five minutes prior to application. The medication is washed off in the morning and if excessive drying and/or irritation is observed a blend cream or lotion may be applied. Unless hands are being treated, hands should be rinsed thoroughly after application. Once desired result is achieved, the occasional use of Salicylic Acid 6% will usually maintain the remission. Hydration by wet packs or baths prior to application can enhance the effect. Excessive repeated application of Salicylic Acid 6% will not necessarily increase its therapeutic benefit, but could result in increased local intolerance and systemic adverse effects such as salicylism (See WARNINGS.).

How is Salicylic Acid 6% Gel Supplied

HOW SUPPLIED SECTION

Salicylic Acid 6% Gel is supplied in:

240 gm Jar70350-2610-2
40 gm Jar70350-2610-1

STORAGE AND HANDLING SECTION

Store at 25°C (77°F); excursion permitted to 15°C - 30°C (59° - 86°F).

Protect from freezing. [See USP Controlled Room Temperature.] Flammable. Keep away from heat and open flame.

SPL UNCLASSIFIED SECTION

Manufactured for:
Solutech Pharmaceuticals LLC
Peoria, AZ 85345

Rx only

PRINCIPAL DISPLAY PANEL - 40 gm Jar Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 70350-2610-1

SALICYLIC ACID 6% GEL

FOR TOPICAL USE ONLY

Net WT. 40 gm

Solutech
PHARMACEUTICALS

PRINCIPAL DISPLAY PANEL - 40 gm Jar Label
PRINCIPAL DISPLAY PANEL - 40 gm Jar Label

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
312893salicylic acid 6 % Topical GelPSN1
312893salicylic acid 0.06 MG/MG Topical GelSCD1
312893salicylic acid 6 % Topical GelSY1

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
70350-2610-12020-01-31C16284748780-19d75b9d1-0de0-f424-e053-dadaa90a57ceSalicylic acid 6% Gel
70350-2610-22020-01-31C16284748780-19d75b9d1-0de0-f424-e053-dadaa90a57ceSalicylic acid 6% Gel

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
70350-2610-1SALICYLIC ACID40 g in 1 JARGEL401
70350-2610-2SALICYLIC ACID240 g in 1 JARGEL2401

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
70350-2610SALICYLIC ACID GEL [SOLUTECH PHARMACEUTICALS LLC]1Legacy NDC, 2 package rows20180330_d5646d2a-caea-4a7a-b107-764d15ad2538.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
70350-2610-1GM - Gram70350-26103d92c691-27c2-4201-b595-7b60e042c64312018-04-19
70350-2610-2GM - Gram70350-2610315e7b96-aaeb-4ba6-b47d-cc40c938184512018-04-19

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 5 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
70350-261070350-2610-2, 70350-2610-1

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 5 matching rows.

Source Document#

Source XML

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
c4287a70-6471-44db-85fd-79250fca76b8d5646d2a-caea-4a7a-b107-764d15ad25382018-03-20Warnings, Adverse reactionsExact identifier
spl id: c4287a70-6471-44db-85fd-79250fca76b8
spl set id: d5646d2a-caea-4a7a-b107-764d15ad2538

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.